Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test

[#item_full_content]ST. LOUIS–(BUSINESS WIRE)–Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board Member to lead Cofactor’s plan to bring precision medicine to immunotherapy. Simultaneously, the company announced that Jarret Glasscock, scientist and Cofactor Genomics founder, will transition into the role of President, Chief Technology Officer (CTO), and Board Member. Parker j

Leave a Reply

Your email address will not be published. Required fields are marked *